EPS for Equity Residential (EQR) Expected At $0.89; 2 Analysts Covering Cerus (CERS)

Analysts expect Equity Residential (NYSE:EQR) to report $0.89 EPS on January, 28 after the close.They anticipate $0.05 EPS change or 5.95% from last quarter’s $0.84 EPS. EQR’s profit would be $330.50M giving it 23.05 P/E if the $0.89 EPS is correct. After having $0.91 EPS previously, Equity Residential’s analysts see -2.20% EPS growth. The stock increased 1.12% or $0.91 during the last trading session, reaching $82.07. About 1.19 million shares traded. Equity Residential (NYSE:EQR) has risen 16.23% since January 16, 2019 and is uptrending. It has outperformed by 16.23% the S&P500. Some Historical EQR News: 24/04/2018 – Equity Residential 1Q Rev $633M; 24/04/2018 – Equity Residential 1Q FFO 71c/Shr; 24/04/2018 – Equity Residential Sees 2Q EPS 36c-EPS 40c; 15/03/2018 – EQUITY RESIDENTIAL BOOSTS QTR DIV TO 54C FROM 50.375C; 24/04/2018 – Equity Residential 1Q Net $211.8M; 24/04/2018 – Equity Residential’s Forecast Beats Projections — Earnings Review; 25/04/2018 – EQUITY RESIDENTIAL COO DAVID SANTEE SPEAKS IN CALL; 25/04/2018 – LONG ISLAND CITY SUPPLY NOT IMPACTING RENTS IN MANHATTAN: EQR; 15/03/2018 – Equity Residential Raises 1st Quarter Dividend to 54c Vs. 50.375c; 24/04/2018 – EQR SEES 2Q NORMALIZED FFO/SHR 77C TO 81C, EST. 80C

Among 2 analysts covering Cerus (NASDAQ:CERS), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Cerus has $800 highest and $700 lowest target. $7.50’s average target is 74.01% above currents $4.31 stock price. Cerus had 5 analyst reports since August 23, 2019 according to SRatingsIntel. Stephens maintained Cerus Corporation (NASDAQ:CERS) on Friday, August 23 with “Overweight” rating. See Cerus Corporation (NASDAQ:CERS) latest ratings:

07/01/2020 Broker: BidaskScore Rating: Sell Upgrade
13/11/2019 Broker: BTIG Research Old Rating: Neutral New Rating: Buy Upgrade
05/10/2019 Broker: BidaskScore Rating: Sell Downgrade
28/08/2019 Broker: Stifel Nicolaus Rating: Buy New Target: $7.0000 Initiates Coverage On
23/08/2019 Broker: Stephens Rating: Overweight New Target: $8.0000 Maintain

Investors sentiment decreased to 0.92 in Q3 2019. Its down 0.54, from 1.46 in 2019Q2. It is negative, as 21 investors sold Cerus Corporation shares while 31 reduced holdings. 14 funds opened positions while 34 raised stakes. 93.27 million shares or 5.12% more from 88.73 million shares in 2019Q2 were reported. Japan-based Sumitomo Mitsui Tru Inc has invested 0.04% in Cerus Corporation (NASDAQ:CERS). Rhumbline Advisers accumulated 184,434 shares. Athena Cap Advsrs owns 22,000 shares or 0.02% of their US portfolio. Stephens Inc Ar owns 939,972 shares. 1.99M are owned by D E Shaw And Inc. 45,462 were reported by Jpmorgan Chase Communication. Moreover, Vanguard Group Inc has 0% invested in Cerus Corporation (NASDAQ:CERS). Morgan Stanley invested in 0% or 331,837 shares. Shufro Rose Ltd Limited Liability Company reported 18,500 shares. Hightower Ltd Company has invested 0% of its portfolio in Cerus Corporation (NASDAQ:CERS). Prudential Financial has 16,643 shares. Amalgamated Commercial Bank owns 23,807 shares. Asset stated it has 3,990 shares. Colony Gp Llc has invested 0.01% of its portfolio in Cerus Corporation (NASDAQ:CERS). Northwestern Mutual Wealth Mngmt Company invested in 0% or 1,000 shares.

The stock decreased 1.15% or $0.05 during the last trading session, reaching $4.31. About 905,200 shares traded or 1.01% up from the average. Cerus Corporation (NASDAQ:CERS) has declined 26.57% since January 16, 2019 and is downtrending. It has underperformed by 26.57% the S&P500. Some Historical CERS News: 26/03/2018 – INTERCEPT PHARMA SAYS LAWSUIT WAS FILED BY A STOCKHOLDER OF CO ON AUG 4, 2017 – SEC FILING; 09/03/2018 – INTERCEPT PHARMACEUTICALS INC ICPT.O : WEDBUSH RAISES TARGET PRICE TO $256 FROM $253; 04/04/2018 – INTERCEPT PHARMACEUTICALS: CONCURRENT $92M PRIVATE PLACEMENT; 04/04/2018 – INTERCEPT PHARMACEUTICALS REPORTS PROPOSED $120M OFFERING & CON; 05/04/2018 – INTERCEPT REPORTS CONCURRENT PLACEMENT OF COMMON SHRS; 08/05/2018 – Intercept Pharmaceuticals 1Q Rev $36M; 16/05/2018 – Cerus Announces Additional BARDA Funding to Support Development of INTERCEPT Blood System for Red Blood Cells; 02/05/2018 – Intercept Pharma Presenting at UBS Conference May 21; 31/05/2018 – Intercept Lead in Fatty Liver Disease Threatened by Upstart; 23/03/2018 – Intercept Announces Multiple New Ocaliva® (obeticholic acid) Data Presentations at the International Liver Congress™ 2018

Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The company has market cap of $612.40 million. The Company’s INTERCEPT Blood System is based on its proprietary technology for controlling biological replication; and targets and inactivates blood-borne pathogens, such as viruses, bacteria, and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma, and red blood cell transfusion products. It currently has negative earnings. The companyÂ’s INTERCEPT Blood Systems for platelets and plasma are designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; and INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion.

More notable recent Cerus Corporation (NASDAQ:CERS) news were published by: Finance.Yahoo.com which released: “Is Cerus (NASDAQ:CERS) Using Debt Sensibly? – Yahoo Finance” on December 30, 2019, also Seekingalpha.com with their article: “Cerus announces interim 2019 product revenue – Seeking Alpha” published on January 13, 2020, Streetinsider.com published: “Cerus (CERS) Announces Preliminary Q4, FY Product Revenue – StreetInsider.com” on January 13, 2020. More interesting news about Cerus Corporation (NASDAQ:CERS) were released by: Finance.Yahoo.com and their article: “How Should Investors React To Cerus Corporation’s (NASDAQ:CERS) CEO Pay? – Yahoo Finance” published on November 12, 2019 as well as Finance.Yahoo.com‘s news article titled: “How Much Are Cerus Corporation (NASDAQ:CERS) Insiders Taking Off The Table? – Yahoo Finance” with publication date: October 13, 2019.

Among 8 analysts covering Equity Residential (NYSE:EQR), 1 have Buy rating, 0 Sell and 7 Hold. Therefore 13% are positive. Equity Residential has $9600 highest and $8000 lowest target. $87.75’s average target is 6.92% above currents $82.07 stock price. Equity Residential had 18 analyst reports since August 23, 2019 according to SRatingsIntel. As per Monday, October 28, the company rating was maintained by Jefferies. The firm has “Hold” rating by BMO Capital Markets given on Tuesday, October 22. The firm has “Hold” rating by Barclays Capital given on Friday, October 11. The rating was maintained by SunTrust with “Hold” on Friday, October 25. The rating was maintained by Morgan Stanley with “Equal-Weight” on Friday, September 6. The firm earned “Hold” rating on Wednesday, October 23 by Stifel Nicolaus. The stock of Equity Residential (NYSE:EQR) earned “Hold” rating by Deutsche Bank on Monday, December 9. The firm has “Buy” rating given on Tuesday, November 5 by Argus Research. SunTrust maintained it with “Hold” rating and $8000 target in Friday, August 23 report.

Investors sentiment decreased to 0.93 in 2019 Q3. Its down 0.20, from 1.13 in 2019Q2. It worsened, as 31 investors sold Equity Residential shares while 159 reduced holdings. 49 funds opened positions while 128 raised stakes. 315.97 million shares or 0.02% less from 316.02 million shares in 2019Q2 were reported. Pictet Asset Management Limited has invested 0.05% of its portfolio in Equity Residential (NYSE:EQR). Andra Ap reported 0.21% in Equity Residential (NYSE:EQR). California Pub Employees Retirement Sys accumulated 3.11M shares or 0.27% of the stock. Anchor Cap Advsr Lc has invested 0.02% in Equity Residential (NYSE:EQR). Green Street Invsts Lc stated it has 201,500 shares. Pinebridge Invests Lp has invested 0.02% in Equity Residential (NYSE:EQR). Mirae Asset Invs Limited has invested 0.03% in Equity Residential (NYSE:EQR). Ci Invs holds 282,570 shares. Griffin Asset Mgmt has invested 0.04% in Equity Residential (NYSE:EQR). Allstate holds 61,898 shares. Moreover, Everence Capital Management has 0.08% invested in Equity Residential (NYSE:EQR). Bankshares Of Nova Scotia reported 71,058 shares. Jane Street Gru Ltd Liability owns 89,144 shares. Checchi Capital Advisers Limited Liability accumulated 2,374 shares or 0.03% of the stock. Bessemer Grp Incorporated owns 4,101 shares for 0% of their portfolio.

More notable recent Equity Residential (NYSE:EQR) news were published by: Finance.Yahoo.com which released: “Equity Residential Announces Fourth Quarter 2019 Earnings Release Date – Yahoo Finance” on January 09, 2020, also Finance.Yahoo.com with their article: “If You Had Bought Equity Residential (NYSE:EQR) Shares Three Years Ago You’d Have Made 46% – Yahoo Finance” published on October 31, 2019, Businesswire.com published: “Equity Residential Declares Fourth Quarter Dividends – Business Wire” on December 19, 2019. More interesting news about Equity Residential (NYSE:EQR) were released by: Fool.com and their article: “How to Identify the Safest REITs to Invest In – Motley Fool” published on January 04, 2020 as well as Finance.Yahoo.com‘s news article titled: “Is Equity Residential (EQR) A Good Stock To Buy ? – Yahoo Finance” with publication date: December 07, 2019.

Cerus Corporation (NASDAQ:CERS) Institutional Positions Chart